June 25, 2022
The approval builds off of liso-cel's (Breyanzi) previous indication for third-line or later treatment in LBCL.
June 24, 2022
BioMarin received a positive CHMP opinion after the FDA delayed val-rox's BLA filing for the second time.
June 24, 2022
B-VEC recently showed efficacy in the phase 3 GEM-3 trial.
June 23, 2022
NfL peaked 1-month post-treatment as expected and returned to near baseline at 12 months.
June 22, 2022
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
June 22, 2022
Annualized bleeding rate fell to 0 at a median of 58 weeks after infusion.
June 21, 2022
Jennifer Buell, PhD, president and chief executive officer, MiNK Therapeutics, discussed different indications for the iNKT therapy AgenT-797.
June 20, 2022
ACE1831 will soon be evaluated in a phase 1, first-in-human, clinical trial.
June 17, 2022
The therapy is now being evaluated in a phase 2 study.
June 16, 2022
Mustang Bio presented data on MB-106 at the 2022 EHA Congress.